MA53671A - Formes cristallines d'un agoniste du récepteur farnésoïde x - Google Patents

Formes cristallines d'un agoniste du récepteur farnésoïde x

Info

Publication number
MA53671A
MA53671A MA053671A MA53671A MA53671A MA 53671 A MA53671 A MA 53671A MA 053671 A MA053671 A MA 053671A MA 53671 A MA53671 A MA 53671A MA 53671 A MA53671 A MA 53671A
Authority
MA
Morocco
Prior art keywords
farnesoid
receptor agonist
crystalline forms
crystalline
forms
Prior art date
Application number
MA053671A
Other languages
English (en)
Inventor
Robert Mansfield
Nicholas D Smith
Original Assignee
Metacrine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metacrine Inc filed Critical Metacrine Inc
Publication of MA53671A publication Critical patent/MA53671A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053671A 2018-09-18 2019-09-17 Formes cristallines d'un agoniste du récepteur farnésoïde x MA53671A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862733007P 2018-09-18 2018-09-18

Publications (1)

Publication Number Publication Date
MA53671A true MA53671A (fr) 2021-07-28

Family

ID=69887984

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053671A MA53671A (fr) 2018-09-18 2019-09-17 Formes cristallines d'un agoniste du récepteur farnésoïde x

Country Status (15)

Country Link
US (1) US20210347736A1 (fr)
EP (1) EP3852749A4 (fr)
JP (1) JP2022500395A (fr)
KR (1) KR20210064261A (fr)
CN (1) CN113056270A (fr)
AU (1) AU2019344905A1 (fr)
BR (1) BR112021004931A2 (fr)
CA (1) CA3112485A1 (fr)
CL (1) CL2021000631A1 (fr)
EA (1) EA202190663A1 (fr)
IL (1) IL281464A (fr)
MA (1) MA53671A (fr)
MX (1) MX2021003083A (fr)
SG (1) SG11202102586RA (fr)
WO (1) WO2020061115A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049173A1 (fr) 2015-09-16 2017-03-23 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
CN113056271B (zh) 2018-09-18 2024-10-29 奥加诺沃公司 法尼醇x受体激动剂及其用途
WO2021188695A1 (fr) 2020-03-18 2021-09-23 Metacrine, Inc. Formulations d'un agoniste du récepteur farnésoïde x
IL296532A (en) 2020-03-18 2022-11-01 Metacrine Inc Crystal forms of farnesoid x receptor agonist
WO2022094816A1 (fr) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Formulation solide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1914205A (zh) * 2003-12-19 2007-02-14 葛兰素集团有限公司 吡唑并[3,4－b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途
EP1734970B1 (fr) * 2004-03-12 2014-12-31 Intercept Pharmaceuticals, Inc. Traitement de la fibrose au moyen de ligands de fxr
JP2010517931A (ja) * 2006-02-14 2010-05-27 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
JP2012516885A (ja) * 2009-02-04 2012-07-26 ファイザー・インク ４−アミノ−７，８−ジヒドロピリド［４，３−ｄ］ピリミジン−５（６Ｈ）−オン誘導体
JP2014500319A (ja) * 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドｘ受容体を調節するための組成物および方法
JP2018536016A (ja) * 2015-09-16 2018-12-06 メタクリン，インク． ファルネソイドｘ受容体アゴニストとその使用
EP3350166A4 (fr) * 2015-09-16 2019-05-01 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
WO2017049173A1 (fr) * 2015-09-16 2017-03-23 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
EP3350158A4 (fr) * 2015-09-16 2019-05-08 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
CN108473484B (zh) * 2015-10-01 2021-06-29 弗门尼舍公司 可用作trpm8调节剂的化合物
WO2017078928A1 (fr) * 2015-11-06 2017-05-11 Salk Institute For Biological Studies Agonistes de fxr et procédés de production et d'utilisation
WO2018170173A1 (fr) * 2017-03-15 2018-09-20 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
LT3609888T (lt) * 2017-03-15 2025-11-10 Farnezoidinio x receptoriaus agonistai ir jų panaudojimas

Also Published As

Publication number Publication date
BR112021004931A2 (pt) 2021-06-01
EA202190663A1 (ru) 2021-08-13
JP2022500395A (ja) 2022-01-04
WO2020061115A1 (fr) 2020-03-26
CA3112485A1 (fr) 2020-03-26
KR20210064261A (ko) 2021-06-02
US20210347736A1 (en) 2021-11-11
EP3852749A4 (fr) 2022-08-24
IL281464A (en) 2021-04-29
CL2021000631A1 (es) 2021-10-01
CN113056270A (zh) 2021-06-29
EP3852749A1 (fr) 2021-07-28
SG11202102586RA (en) 2021-04-29
MX2021003083A (es) 2021-05-27
AU2019344905A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MA53671A (fr) Formes cristallines d'un agoniste du récepteur farnésoïde x
IL283362A (en) Thrβ receptor agonist compound and preparation method and use thereof
EP4069686A4 (fr) Agoniste du récepteur glp-1
EP3965765A4 (fr) Promédicaments d'antagonistes du récepteur opioïde
LT3762380T (lt) Fenilpirolidinono formilpeptido 2 receptoriaus antagonistai
DK3810201T5 (da) GIP/GLP1-agonist-sammensætninger
MA54458A (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
MA54526A (fr) NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta
MA47596A (fr) Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan
EP3870181A4 (fr) Formes cristallines d'un inhibiteur d'alk2
IL286218A (en) Solid state forms of ripretinib
IL285510A (en) Substituted amide compounds useful as farnesoid x receptor modulators
DK4508045T3 (da) Citratsalt-former af en muskarinreceptor-agonist
DK3746609T3 (da) Tilslutningsindretning for en toiletkumme
EP4076492A4 (fr) Composés antagonistes du pcsk
EP3746421A4 (fr) Antagonistes du récepteur muscarinique de l'acétylcholine m4
EP3897660A4 (fr) Nouvelles formes cristallines d'un composé de nrtti
MA56001A (fr) Formes de sel cristallin d'un inhibiteur de kinase
EP3863629A4 (fr) Promédicaments d'antagonistes du cgrp
IL289453A (en) Process for the preparation of ridinilazole and crystalline forms thereof
MA54638A (fr) Formes cristallines d'un stimulateur de sgc
MA55801A (fr) Formes solides d'un inhibiteur de glyt1
EP4121010A4 (fr) Formes cristallines d'un agoniste du récepteur farnésoïde x
EP4006033A4 (fr) Antagoniste du récepteur de l'adénosine
IL280199A (en) Receptor for vista